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Background: In view of the importance of beta cells in glucose homeostasis and the profound repercussions of
beta cell pathology on human health, the acquisition of tools to study pancreatic islet function is essential for the
design of alternative novel therapies for diabetes. One promising approach toward this goal involves the
modification of gene expression profile of beta cells.
Results: This study describes a new method of gene and siRNA delivery into human pancreatic islets by
microporation technology. We demonstrated that mild islet distention with accutase greatly enhanced the
transfection efficiency without compromising in vitro function (secretion, apoptosis and viability). As an example,
the recently identified gene involved in type 2 diabetes, ZnT8, can be over-expressed or silenced by RNA
interference using this technology. Microporation can also be used on rodent islets.
Conclusions: Taken together, our results demonstrate that microporation technology can be used to modify gene
expression in whole rodent and human islets without altering their in vitro function and will be key to the
elucidation of the factors responsible for proper islet function.
Background
Establishing robust gene delivery systems that result in
efficient transfection of the pancreatic-beta cells is a
prerequisite to the study of type 1 and 2 diabetes and
may also represent a critical step toward clinical applica-
tion. Numerous report in the literature describe the
application of gene over-expression and silencing in
beta-cells derived cell-lines to study beta-cell function
and the mechanisms behind type 1 and 2 diabetes
pathologies. However, the findings in beta cell lines are
not always congruous with results in primary islet beta
cells, underlying the necessity of studying beta-cells in
their native environment [1,2].
Modulation of gene expression in the context of intact
pancreatic islets is particularly difficult because of their
three dimensional structure (50-500 μm in diameter),
making physical access to the islet core difficult. Islets
are organized in organoid cell clusters of 1000 to 2000
cells made up of four types of endocrine secreting cells,
the insulin containing b-cells, the glucagon containing
a-cells, the somatostatin containing δ-cells and the pan-
creatic polypeptide-producing (PP) cells [3]. Over the
past decades, numerous attempts have been made to
transfect or transduce intact cells using lipid-mediated
plasmid delivery [4,5], adenovirus vectors [6-8], lenti-
virus vectors [9] and magnetic nanocarriers [10]. How-
ever, the major obstacle of these studies is that only
cells at the periphery of islets become efficiently trans-
fected or transduced.
In the present study, we herein demonstrate successful
transfection of plasmids and siRNA to whole suspension
cultured rodent and human pancreatic islets. First, a
mild digestion with accutase enzyme was found to be
necessary to predistend (ie without dissociation) human
islets and enhance accessibility to core cells. Subse-
quently, rodent islets or predistended human islets were
subjected to microporation in the presence of the plas-
mid of interest or siRNA. Using GFP vector and confo-
cal microscopy, we have been able to show that most of
the rodent and human islet cells (>70%) have been effi-
ciently transfected. Furthermore, we demonstrated that
the viability and insulin secretory function of the human
transfected islets were not altered in that they responded * Correspondence: bruno.lefebvre@inserm.fr
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cacy of transfection and silencing in human islets has
been confirmed using the recently identified diabetes-
linked zinc transporter ZnT8. Taken together, our
results demonstrated that microporation of rodent islets
or human islets after predistension is a new robust tool
to study gene functions in the context of whole islets.
Results
Demonstration of human core islet targeting after
accutase treatment
To evaluate the transfection efficiency, confocal micro-
scopy and estimation of islet viability and metabolism
were used. Adenoviruses (Ad)-GFP or transfections
were carried out as described in Materials and Methods.
As shown in Figure 1A, adenovirus was able to infect
the intact human islets but eGFP staining (2 day post-
transduction) revealed only surface expression, as pre-
viously reported [11]. In addition, we found a significant
decrease in the ATP level suggesting that adenoviral
transduction altered islet viability (data not shown).
Electroporation (EP) or microporation (MP) technol-
ogy demonstrated to be highly efficient in primary cells
and cell lines that are very difficult to transfect [12]. As
shown in Figure 1B, MP of intact islet with eGFP plas-
mid led to very low transfection efficiency (2 days post-
transfection). The same results were found for different
electrical parameters (data not shown). However, pre-
treatment with accutase greatly enhanced the number of
GFP positive cells with a staining of peripheral cells as
well as core islets (Figure 1C). Using the same para-
meters, 70% of mouse islet cells were found to be trans-
fected observed by eGFP staining without predistention
step (Figure 1D).
Viability and human islet function were not impaired
after accutase pretreatment and transfection
To determine whether gene transfer using accutase pre-
treatment and microporation altered islet viability, we
first used trypan blue staining, ATP level and DNA frag-
mentation as indicators of viable cells. No significant
differences were found in the viability, ATP level (data
not shown) and apoptotic index (Figure 2A) between
control islets and 2 day post-transfected islets after
accutase treatment.
Islets regulate insulin release physiologically in
response to glucose. To determine if MP of islets after
accutase pretreatment maintains normal regulated insu-
lin secretion, an essential requirement for any gene
function studies, insulin content and glucose stimulated
insulin secretion were determined on control and 2 day
post-transfected islets. As shown in Figure 2B and 2C,
both insulin content and stimulation index were com-
parable between the two conditions.
These results demonstrated that accutase pretreatment
combined with MP of islets does not affect the viability
and function of human islets.
Validation of gene transfer and silencing efficacy by
Quantitative RT-PCR
Final validation of gene transfection and silencing effica-
cies was obtained by quantitative RT-PCR for zinc
transporter ZnT8. Level of ZnT8 expression was first
assessed on transfected human islets with eGFP or
eGFP-ZnT8 plasmid. After two days, we observed a
500-fold increase in the level of ZnT8 mRNA as com-
pared to control (Figure 3A). A significant > 70% reduc-
tion in endogenous ZnT8 mRNA transcript levels was
observed in human islets transfected with the siZnT8
(5 and 10 pmol/l) as compared with control islets or
transfected with scrambled siRNA after 4 days.
Taken together, these data demonstrate that accutase
pretreatment and MP is an efficient method for gene
expression and silencing in human islets.
Discussion
As the beta-cell plays a central role in both type 1 and type
2 diabetes, the acquisition of tools to study beta cell func-
tion represents a key research for developing alternative
therapies. One approach used was the development of
beta-cells derived cell-lines. Although they represent valu-
able tools for the study of molecular events underlying
beta-cell function and dysfunction, the behavior of these
cell lines does not perfectly mimic the beta-cell physiology
[1]. To date, most islet transfections have been performed
using viral vectors. However, limited loading capacity of
genes has been observed in most of the cases [13,14]. In
addition, our results suggested that adenovirus transduc-
tion perturbed human islet viability. Liposomal gene
carriers have often resulted in ineffective gene expression,
islet toxicity at high liposome/plasmid ratios and poor
insulin secretion after transfection [5]. The disadvantages
of viral or liposomal vectors have triggered us to the devel-
opment of alternative methods. First, to overcome the lim-
ited loading capacity of genes in human islets, we used
mild digestion with accutase. By using this pretreatment,
we achieved much higher transfection efficiency for all
non-viral transfection procedure tested. Efficient delivery
in mouse islets did not require predistention and may be
related to species differences in regard to cytoarchitecture
[3]. In addition, we demonstrated that islet viability and
function were not affected by this procedure. This disten-
sion technique was previously described in our lab to
improve penetration of Newport Green, a fluorescent zinc
chelator into the human islet core [15]. Second, to over-
come islet toxicity often observed during the transfection
procedure, we used an electroroporation-based technol-
ogy. We choose to test microporation technology, a
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which lacks the deleterious effects of cuvette-based elec-
troporation methods including pH variation, temperature
increase, turbulence, and generation of metal ions as
described by NanoEnTek Inc (Seoul, Korea). In addition, it
has been shown that this technology has beneficial features
for transfecting slowly dividing cells such as primary cells
[12]. By using the combine methodology of accutase pre-
treatment and microporation, we have been able to
achieve high transfection efficiency without affecting
human islet survival and function.
Conclusion
We found that transfection of human islets using accu-
tase distention and microroporation can achieve efficient
gene expression and silencing without impairing islet
function and represents a suitable strategy to study gene
function in human islets. Microporation also works in
rodent islets.
Methods
Human and mouse islet isolation
Human pancreases were harvested from adult brain-
dead donors in accordance with French Regulations and
with the local Institutional Ethical Committee. Clinical
grade pancreatic islets in number insufficient for trans-
plantation were isolated as described [16]. Islet number
was determined on samples of each preparation after
dithizone staining and expressed as equivalent number
of islets (IE) [17]. All experiments were realized at least
on 3 different donors of >80% purity. A total of 9
human islet preparations were used for this study.
Figure 1 eGFP expression in human and mouse islets following adenoviral and microporation transfection delivery. (A) GFP expression
of human islets infected with Ad-GFP. (B) GFP expression of human islets microporated with an eGFP plasmid. (C) GFP expression of human
islets pretreated with accutase and microporated with an eGFP plasmid. (D) GFP expression of mouse islets microporated with an eGFP plasmid
by fluorescent microscopy 12 or 24 h after microporation.
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room with a 12-hour light/dark cycle and were allowed
free access to food and water conformed to guidelines
of the Bremen Senate for Work, Health, Women, Youth
and Social Affairs and from the Bremen Senate in agree-
ment with the National Institutes of Health animal care
guidelines and §8 of the German animal protection law.
Mouse islets from C57Bl/6J mice were isolated and
cultured as described previously [18]. The islets were
then pre-cultured in RPMI-1640 medium containing
11.1 mM glucose, 100 U/ml penicillin, 100 μg/ml
streptomycin and 10% FCS (Invitrogen, Scotland)
Cell culture and transfection
Purified human islets were cultured in CMRL 1066
medium (Gibco BRL, Life Technologies) containing
0.6% BSA (Roche Diagnostics, France), penicillin (100
μUI/ml), streptomycin (100 μg/ml) [19].
Human islet transfections were performed using
microporation (Microporator MP100, Digital Bio, Lab-
tech France) after accutase (PPA Laboratories GmbH,
Austria) pretreatment (2500 IE incubated at 37°C for 2
min). Transfection experiments were performed between
18 h to 3 day post-isolation.
In a preliminary study, we tested in terms of islet
function (insulin secretion), apoptosis and viability the
24 different experimental microporation protocols pro-
posed by the manufacturer Digital Bio (South Korea)
using an eGFP plasmid and determined the optimal pro-
gram: 2 pulses of 1400 V, 20 ms with 1 μgo fp l a s m i d
for 2500 IE for human islets.
For ZnT8 studies, control eGFP or ZnT8-eGFP (kind
gift of Dr Chimienti) or siRNA to ZnT8 obtained from
Dharmacon (Perbio Science, France) were microporated
according to the above protocol.
As a comparison adenoviral transduction (adenoviral
(Ad)-GFP) was performed as follows:2500 IE placed in
the CMRL BSA medium, were transduced (MOI 60) for
4 hours. The islets were then washed with medium and
incubated for an additional 48 h.
For mouse islets, islets were transferred into a 24-well
plate 24 h after isolation and transfected with 2 μg/ml
CMV-eGFP using a standard program of 30 ms, 2
bursts and 950 V with Microporator MP100 according
to the manufacturer’s instructions. Transfection effi-
ciency was monitored at 12-24 h by analyzing GFP-
positive islet cells under a fluorescent microscope
Nikon MEA53200 (Nikon GmbH Duesseldorf,
Germany) and images were acquired using NIS-
Elements software (Nikon).
Estimation of islet cell viability
Islet viability was assessed after dithizone and trypan
blue staining on 3 aliquots of 80 IE per condition.
Figure 2 Human islet metabolic parameters were not modified
upon accutase pretreatment and microporation. (A) apoptotic
index, (B) insulin content and (C) stimulation index were measured
in control human islets or overexpressing GFP-human islets after 48
h culture. Values are means +/- SEM of islets from n = 3 pancreases.
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condition by a luminescence ATP detection assay sys-
tem as described by the manufacturer (ATPlite, Perkin
Elmer).
Insulin content and glucose stimulated insulin release
(GSIS)
Insulin content was assayed using a radioimmunoassay
kit (CIS bio International) in the lysate of 3 aliquots of
40 IE per condition. GSIS was determined by static
incubations of islets for 1 hour with low glucose
(2.8 mmol/l, basal) followed by 1 hour with high glucose
(20 mmol/l, stimulated). Stimulation indexes defined as
the ratio of stimulated to basal insulin release were esti-
mated on 5 aliquots of 40 IE per condition.
Determination of DNA fragmentation
The specific determination of mono-and oligonucleo-
somes in the cytoplasmic fraction of islet lysates (3 ali-
quots of 160 IE per condition) was achieved by
quantitative sandwich enzyme-immunoassay using
mouse monoclonal antibodies against DNA and histones
(cell death detection ELISA kit from Roche Molecular
Biochemicals).
RNA preparation and real-time PCR
Total RNA was prepared using RNeasy Minikit (Qia-
gen). Purified RNA was adjusted to 1 μg/μla n di t s
integrity was assessed with the Agilent RNA 6000 chips
coupled with the Agilent 2100 Bioanalyzer (Agilent
Technologies), by visualizing the 18S and 28S ribosomal
ribonucleic acid (rRNA). Reverse transcription (RT) was
performed using random hexamers as recommended by
the manufacturer (Applied Biosystems). cDNAs were
analyzed by PCR amplification using the TaqMan PCR
master mix (Applied Biosystems) and a mix of RPLO
primers and probes. The different probes were pur-
chased from Applied Biosystems (assay on demand kit).
Reactions (40 cycles) and data analysis were carried out
with an ABI Prism 7900 (Perkin-Elmer).
Statistical study
Results are presented as means ± SEM. The statistical
differences between the groups are analyzed with one-
way ANOVA and the Fisher’s Least Significant Differ-
ence test using Statview 4.1 software (Abacus, Berkeley,
CA).
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